Replenish: Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients

Sponsor
King Abdullah International Medical Research Center (Other)
Overall Status
Completed
CT.gov ID
NCT03480555
Collaborator
(none)
40
2
2
15.8
20
1.3

Study Details

Study Description

Brief Summary

In this study, we will explore the feasibility of a randomized controlled trial that will compare high protein dose from ICU day 6 to 14 with moderate protein intake.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Replenish Protein
  • Dietary Supplement: Standard protein
N/A

Detailed Description

Patients will be recruited on day 1-2 of ICU admission. On day 5, patients will be randomized into one of the two intervention arms;

Replenish Protein group:

Patients randomized to this group will receive 2 g of protein/kg/day (acceptable range 1.8 - 2.2 g of protein/kg/day) for day 6-14.

Standard Protein group:

Patients randomized to this group will receive protein at 0.8 - 1.0 g of protein/kg/day for day 6-14

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients: Feasibility Randomized Controlled Trial
Actual Study Start Date :
May 16, 2018
Actual Primary Completion Date :
May 10, 2019
Actual Study Completion Date :
Sep 10, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Replenish Protein group

Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.

Dietary Supplement: Replenish Protein
Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
Other Names:
  • Intervention group
  • Other: Standard Protein group

    Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14

    Dietary Supplement: Standard protein
    Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
    Other Names:
  • Control group
  • Outcome Measures

    Primary Outcome Measures

    1. Recruitment [6 months]

      Recruitment log

    2. Retention rate [14 days]

      withdrawals

    3. Achieved protein intake [14 days]

      Feeding data

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion criteria

    1. Age ≥ 18 years

    2. Mechanically ventilated

    3. Receiving enteral feeding via nasogastric/orogastric or duodenal or PEG or jejunostomy tubes and

    4. Expected to stay ≥ 1 week in the ICU

    Exclusion criteria

    1. Lack of commitment to ongoing life support, which includes;
    • Terminal Illness (Malignancy or irreversible condition with 6 month mortality > 50%)

    • DNR order in the first 48 hours and brain death within 48 hours of admission) (Don't include the presence of a "Do Not Resuscitate" order alone, if there is a commitment to ongoing life support).

    1. Patients not fed within 48 hours of admission

    2. Patients on total parenteral nutrition (TPN)

    3. Patients being fed orally

    4. Chronic renal failure

    5. Chronic liver disease

    6. Renal replacement therapy

    7. Pregnancy.

    8. Kidney transplant

    9. Post-liver transplant.

    10. Post cardiac arrest.

    11. Burn patients.

    12. Prisoners

    Screened patients will be screened again for eligibility at day 5, should be mechanically ventilated and expected to stay ≥ 3 days in the ICU. At this point, patients will be excluded if they meet the following;

    1. New onset renal replacement therapy.

    2. Acute Kidney Injury (serum creatinine > 3 times the preacute level or serum creatinine

    350mmol/L with a recent increase of >44 mmols/L)

    1. Significant liver impairment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 King Abdulaziz Medical city Jeddah Saudi Arabia 21423
    2 King Abdulaziz Medical city Riyadh Saudi Arabia 11426

    Sponsors and Collaborators

    • King Abdullah International Medical Research Center

    Investigators

    • Principal Investigator: Yaseen M Arabi, MD, King Abdulaziz Medical City-Ministry of National Guard

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    King Abdullah International Medical Research Center
    ClinicalTrials.gov Identifier:
    NCT03480555
    Other Study ID Numbers:
    • RC17/252/R
    First Posted:
    Mar 29, 2018
    Last Update Posted:
    Jan 5, 2021
    Last Verified:
    Dec 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by King Abdullah International Medical Research Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 5, 2021